Zymeworks, Jazz agree to licensing deal for cancer drug


Shares of Zymeworks Inc. ZYME, +8.38% gained 8.4% in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -1.78% for its cancer drug, zanidatamab, which is currently being tested as a treatment for some HER2-expressing cancers. Jazz will pay Zymeworks $50 million upfront. Including all regulatory and commercial milestone payments, the deal, which is expected to close before the end of the year, is worth up to a total $1.7 billion. Zymeworks’ stock is down 66.7% this year, while the S&P 500 SPX, -0.43% has declined 21.9%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleCoronavirus Update: Trump aides interfered with CDC’s communications with American public to downplay COVID risks, report finds
Next articleWhat every investor should consider on 35th anniversary of ‘Black Monday’ crash


Please enter your comment!
Please enter your name here